MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. today announced the Centers for Medicare & Medicaid Services (CMS) has approved New Technology Add-on Payments (NTAP) for the RNS System, the world’s only commercially available implantable closed-loop responsive neurostimulator system. The NTAP program recognizes new technologies that provide substantial clinical improvement over existing therapies, and is designed to support timely access to innovative technologies for Medicare beneficiaries.
NeuroPace received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for the RNS System in November 2013. It is approved as a treatment for adults with partial onset seizures with one or two seizure onset zones whose seizures have not been controlled with two or more antiepileptic drugs.
Help employers find you! Check out all the jobs and post your resume.
